This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|February 1, 2021
Cytiva Acquires Vanrx Pharmasystems
Cytiva acquired Vanrx Pharmasystems, a Canadian manufacturer of robotic aseptic filling equipment.
Advertisement
Cytiva announced in a Feb. 1, 2021 press release that it had acquired Vanrx Pharmasystems, a Canadian company that makes robotic aseptic filling machines. It is Cytiva’s first acquisition since becoming a Danaher operating company in April 2020, and it will complement Cytiva’s biopharmaceutical manufacturing solutions.
Cytiva noted in the release that, with the trend to smaller batches, a complete bioprocessing workflow should include aseptic filling solutions. Olivier Loeillot, vice-president and head of BioProcess, Cytiva, said in the release that the Vanrx technology would make Cytiva an “idea to injection” company and enhance its Cytiva FlexFactory platforms and KUBio modular facilities for bioprocessing.
Vanrx’s flagship products automate aseptic filling using robotics within closed, gloveless isolators. The SA25 Aseptic Filling Workcell and Microcell Vial Filler are standardized, flexible systems that provide a fast path to filling capacity as the final step in manufacturing clinical and commercial biopharmaceuticals.
Chris Procyshyn, Vanrx CEO, who founded the company in 2007 with co-founder Ross Gold, said in the release, “We created Vanrx to enable every company to manufacture safe and cost-effective injectable therapies. Our own experience told us that new technologies are needed to support next-generation therapies and personalized medicine. Cytiva is a perfect home for what we have built. Thanks to their reach, we will be able to help our current and future customers change the lives of even more patients around the world.”
Vanrx currently has over 120 associates, and all have been offered employment with Cytiva.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5